Novoclem announces issuance of patent covering a core technology underlying its Cystic Fibrosis therapeutic development program

Newly issued patent covers water soluble polyglucosamine compositions which release Nitric Oxide in a controlled and targeted manner

Novoclem Therapeutics today announced that U.S. Patent No. 9,850,322, “Water Soluble Nitric Oxide Releasing Polyglucosamines and Uses Thereof”, was issued Dec. 26, 2017. The patent lists Mark Schoenfisch and Yuan Lu as inventors and is assigned to the University of North Carolina at Chapel Hill. It is exclusively licensed to Novoclem Therapeutics for the treatment of respiratory diseases. The patent covers Novoclem’s lead inhalable drug candidate, BIOC51, which has been designated as a “Qualified Infectious Disease Product” (QIDP) by the U.S. Food & Drug Administration for treatment of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis.